


Idebenone



Idebenone was developed initially to treat Alzheimer's Disease and is a synthetic analog of CoQ10.

Nootropic effects and Alzheimer's disease ^[1]

Idebenone improved learning and memory in experiments with mice^[5] In humans, evaluation of Surrogate endpoints like electroretinography, auditory evoked potentials and visual analogue scales also suggested positive nootropic effects^[6] but larger studies with hard endpoints are missing.

Research on idebenone as a potential therapy of Alzheimer's disease have been inconsistent, but there may be a trend for a slight benefit^{[7][8]} In May 1998, the approval for this indication was cancelled in Japan due to the lack of proven effects. In some European countries, the drug is available for the treatment of individual patients in special cases^[9]

References and Further Readings

1. Idebenone - <https://en.wikipedia.org/wiki/Idebenone>
2. Idebenone Next Generation Co q10 - <http://idebenone.net/>
3. Idebenone - Journal of Neurochemistry Publishes Idebenone Article - <http://idebenone.net/jnc>
4. Safety and Efficacy of Idebenone versus Tacrine in Patients with Alzheimer's Disease
5. Liu, XJ; Wu, WT (1999). "Effects of ligustrazine, tanshinone II A, ubiquinone, and idebenone on mouse water maze performance." *Zhongguo yao li xue bao = Acta pharmacologica Sinica* **20** (11): 987–90. [PMID 11270979](https://pubmed.ncbi.nlm.nih.gov/11270979/).
6. Schaffler, K; Hadler, D; Stark, M (1998). "Dose-effect relationship of idebenone in an experimental cerebral deficit model. Pilot study in healthy young volunteers with piracetam as reference drug." *Arzneimittel-Forschung* **48** (7): 720–6. [PMID 9706371](https://pubmed.ncbi.nlm.nih.gov/9706371/).
7. Gutzmann, H; Kühl, KP; Hadler, D; Rapp, MA (2002). "Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study." *Pharmacopsychiatry* **35** (1): 12–8. [doi:10.1055/s-2002-19833](https://doi.org/10.1055/s-2002-19833). [PMID 11819153](https://pubmed.ncbi.nlm.nih.gov/11819153/).
8. Parnetti, L; Senin, U; Mecocci, P (1997). "Cognitive enhancement therapy for Alzheimer's disease. The way forward." *Drugs* **53** (5): 752–68. [doi:10.2165/00003495-199753050-00003](https://doi.org/10.2165/00003495-199753050-00003). [PMID 9129864](https://pubmed.ncbi.nlm.nih.gov/9129864/).

9. ["CHMP Assessment Report for Sovrima". European Medicines Agency.](#) 20 November 2008. pp. 6, 9–11, 67f.